Your browser doesn't support javascript.
loading
SLC25A25-AS1 over-expression could be predicted the dismal prognosis and was related to the immune microenvironment in prostate cancer.
Zhao, Ying-Ying; Xiang, Qian-Ming; Chen, Jia-Li; Zhang, Li; Zheng, Wei-Long; Ke, Di; Shi, Rong-Shu; Yang, Kong-Wu.
Affiliation
  • Zhao YY; Department of Radiology, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
  • Xiang QM; Department of Radiology, Fuqing City Hospital Affiliated to Fujian Medical University, Fuqing, China.
  • Chen JL; Department of General Surgery, The First Affiliated Hospital of Kunming Medical University, Kunming, China.
  • Zhang L; Department of Radiology, Fuqing City Hospital Affiliated to Fujian Medical University, Fuqing, China.
  • Zheng WL; Department of Radiology, Fuqing City Hospital Affiliated to Fujian Medical University, Fuqing, China.
  • Ke D; Department of Radiology, Fuqing City Hospital Affiliated to Fujian Medical University, Fuqing, China.
  • Shi RS; Department of Radiology, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
  • Yang KW; Department of Radiology, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Front Oncol ; 12: 990247, 2022.
Article in En | MEDLINE | ID: mdl-36338724
ABSTRACT
It has been established that long-chain coding RNA (lncRNA) SLC25A25-AS1 is associated with cancer progression. However, the roles and mechanisms of SLC25A25-AS1 in prostate cancer (PC) have not been reported in the literature. The present study explored the relationship between SLC25A25-AS1 expression and PC progression via comprehensive analysis. The pan-cancer expression of SLC25A25-AS1 was identified using data from The Cancer Genome Atlas (TCGA) database and tissue specimens from our hospital. The expression levels of SLC25A25-AS1 in various subgroups based on the clinical features were identified. The prognostic value of SLC25A25-AS1 and SLC25A25-AS1 co-expressed lncRNAs in PC patients was assessed by survival analysis and ROC analysis, and prognosis-related risk models of SLC25A25-AS1 were constructed. The relationship between SLC25A25-AS1 and the PC immune microenvironment was investigated using correlation analysis. SLC25A25-AS1 expression in PC was significantly increased and correlated with the T stage, clinical stage, Gleason score (GS), and dismal prognosis. SLC25A25-AS1 overexpression exhibited good performance in evaluating the prognosis of PC patients. The area under the curves (AUCs) of the 1-, 3-, and 5-year overall survival (OS) for SLC25A25-AS1 was 1, 0.876, and 0.749. Moreover, the AUCs for the 1-, 3-, and 5-year progress free interval (PFI) for SLC25A25-AS1 were 0.731, 0.701, and 0.718. SLC25A25-AS1 overexpression correlated with the infiltration of CD8 T cells, interstitial dendritic cells (IDC), macrophages and other cells. AC020558.2, ZNF32-AS2, AP4B1-AS1, AL355488.1, AC109460.3, SNHG1, C3orf35, LMNTD2-AS1, and AL365330.1 were significantly associated with SLC25A25-AS1 expression, and short OS and PFI in PC patients. The risk models of the SLC25A25-AS1-related lncRNAs were associated with a dismal prognosis in PC. Overall, SLC25A25-AS1 expression was increased in PC and related to the prognosis and PC immune microenvironment. The risk model of SLC25A25-AS1 have huge prospect for application as prognostic tools in PC.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies / Risk_factors_studies Language: En Journal: Front Oncol Year: 2022 Document type: Article Affiliation country: China

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies / Risk_factors_studies Language: En Journal: Front Oncol Year: 2022 Document type: Article Affiliation country: China